This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in Orlando, Florida.

The schedule for tivozanib poster presentations at ASCO GU is as follows:

 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (B3)

(Abstract #350) Title: Overall Survival Results from a Phase 3 Study of Tivozanib Hydrochloride vs Sorafenib in Patients with Renal Cell Carcinoma

Presenter: Robert Motzer, M.D.

 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (B7)

(Abstract #354) Title: Subgroup Analyses of a Phase 3 Trial Comparing Tivozanib Hydrochloride vs Sorafenib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma (mRCC)

Presenter: Thomas Hutson, D.O., Pharm.D.

 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (B8)

(Abstract #355) Title: Treatment Benefit of Tivozanib Hydrochloride versus Sorafenib on Health-Related Quality of Life among Patients with Advanced/Metastatic Renal Cell Carcinoma (mRCC): TIVO-1 Study Results

Presenter: David Cella, Ph.D.

 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (C1)

(Abstract #364) Title: Efficacy and Safety Data from Patients with Advanced Renal Cell Cancer Treated with Tivozanib Hydrochloride After Progression on Sorafenib

Presenter: Robert Motzer, M.D.

 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (B14)

(Abstract #361) Title: Relationship of Hypoxia Signature with Variant Subgroup of Clear Cell Renal Cell Carcinoma (ccRCC) and its Association with Clinical Activity on Tivozanib Hydrochloride

Presenter: Murray Robinson, Ph.D.

About Kidney Cancer

Advanced RCC, or kidney cancer, is the ninth most commonly diagnosed cancer in men and women in the U.S. 1 Worldwide it is estimated that more than 250,000 people are diagnosed and more than 100,000 people die from the disease each year. 2 RCC accounts for more than 90 percent of all kidney cancers. 3 Currently available therapies provide less than one year of median progression-free survival (PFS) in treatment naive patients and are associated with significant toxicities. 4 These toxicities not only lead to high rates of dose reductions and interruptions (potentially compromising efficacy), but also can impact a patient’s quality of daily living. 5

About Tivozanib

Tivozanib is a potent, selective and long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor for which positive results from a Phase 3 clinical study in advanced RCC have been reported, and is being evaluated in other tumors.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs